We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchison China Meditech Ltd | LSE:0J7G | London | Ordinary Share | HUTCHISON CHINA MEDITECH ADR REPRESENTIN |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 33.29 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
From May 2021 to May 2024
TIDMHCM
RNS Number : 1637E
Hutchmed (China) Limited
09 March 2022
Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Wednesday, March 9, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2021 annual results of HUTCHMED on March 3, 2022, the following awards granted under the Long Term Incentive Plan ("LTIP") on March 15, 2017 and April 20, 2020 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 8, 2022:-
Hot Features
Premium
Number of American
depositary shares
Award Holders ("ADS")
Person Discharging Managerial Responsibilities
Dr Weiguo Su (Executive Director, Chief Executive
Officer and Chief Scientific Officer) 18,770
Mr Johnny Cheng (Executive Director and Chief Financial
Officer) 4,198
Total 22,968
===================
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
(a) Dr Weiguo Su
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director, Chief Executive Officer and Chief
Scientific Officer
------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name HUTCHMED (China) Limited
------------------------------------------------------- -------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing five Ordinary Shares of US$0.10
instrument ADS ISIN: US44842L1035
Identification code
------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction (i) Vesting of awards granted on March 15, 2017 under
HUTCHMED's LTIP
(ii) Vesting of awards granted on April 20, 2020
under HUTCHMED's LTIP
------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
( i) Nil 3,754 ADS
--------- -----------
(ii) Nil 15,016 ADS
--------- -----------
------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2022-03-08
------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------------------------- -------------------------------------------------------
(b) Mr Johnny Cheng
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Mr Johnny Cheng
------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Financial Officer
------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name HUTCHMED (China) Limited
------------------------------------------------------- -------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing five Ordinary Shares of US$0.10
instrument ADS ISIN: US44842L1035
Identification code
------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on April 20, 2020 under
HUTCHMED's LTIP
------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Nil 4,198 ADS
----------
------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2022-03-08
------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------------------------- -------------------------------------------------------
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries Mark Lee, Senior Vice President +852 2121 8200 Annie Cheng, Vice President +1 (973) 567 3786 Media Enquiries Americas - Brad Miles, +1 (917) 570 7340 (Mobile) Solebury Trout bmiles@troutgroup.com Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) FTI Consulting HUTCHMED@fticonsulting.com Asia - Zhou Yi, +852 97 83 6894 (Mobile) Brunswick HUTCHMED@brunswickgroup.com Nominated Advisor Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGRGDXRDGDGDC
(END) Dow Jones Newswires
March 09, 2022 03:30 ET (08:30 GMT)
1 Year Hutchison China Meditech Chart |
1 Month Hutchison China Meditech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
